1-10 of 10
Fadi G. Haddad
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission

Clinical Trials & Observations Brief Report
Elias Jabbour, Fadi G. Haddad, Nicholas J. Short, Jayastu Senapati, Nitin Jain, Koji Sasaki, Jeffrey Jorgensen, Sa A. Wang, Yesid Alvarado, Xuemei Wang, Courtney DiNardo, Lucia Masarova, Tapan Kadia, Rebecca S. Garris, Farhad Ravandi, Hagop Kantarjian
Journal: Blood
Blood (2024) 143 (5): 417–421.
https://doi.org/10.1182/blood.2023022330
Published: 2024
Includes: Supplemental data
Journal Articles

Phase 2 Trial of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

Wei-Ying Jen, Elias Jabbour, Fadi G. Haddad, Nicholas J. Short, Nitin Jain, Tapan M. Kadia, Naval Daver, Gautam Borthakur, Lewis Nasr, Courtney D. DiNardo, Marianne Zoghbi, Jovitta Jacob, Edith Roy, Christopher Loiselle, Anna Milton, Juan Rivera, Rebecca Garris, Farhad Ravandi, Hagop M. Kantarjian
Journal: Blood
Blood (2023) 142 (Supplement 1): 2878.
https://doi.org/10.1182/blood-2023-182982
Published: 2023
Journal Articles

Time-Limited Therapy with Zanubrutinib Plus Rituximab in Treatment-Naïve Chronic Lymphocytic Leukemia: Early Results of an Ongoing Phase 2 Trial

Jan A. Burger, Ekaterina Kim, Mariela Sivina, Thomas Mathew, Danielle E. Hammond, Fadi G. Haddad, Alessandra Ferrajoli, William G. Wierda
Journal: Blood
Blood (2023) 142 (Supplement 1): 6524.
https://doi.org/10.1182/blood-2023-178774
Published: 2023
Journal Articles

Impact of High-Risk Cytogenetics (HR-CTG) on the Outcome of Newly Diagnosed Adult Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL) Treated with Frontline Blinatumomab (Blina) and/or Inotuzumab Ozogamicin (Ino) Containing Hypercvad (HCVAD) Therapy

Jayastu Senapati, Elias Jabbour, Nicholas J. Short, Guilin Tang, Fadi G. Haddad, Nitin Jain, Ghayas C. Issa, Tapan M. Kadia, Naval Daver, Alessandra Ferrajoli, Monica Kwari, Guillermo Garcia-Manero, Guillermo Montalban-Bravo, Patrice Eric Nasnas, Naveen Pemmaraju, Rebecca Garris, Farhad Ravandi, Hagop M. Kantarjian
Journal: Blood
Blood (2023) 142 (Supplement 1): 1500.
https://doi.org/10.1182/blood-2023-181379
Published: 2023
Journal Articles

Cladribine, High-Dose AraC, Plus Gemtuzumab Ozogamicin (CLAG-GO) As Frontline Intensive Therapy for Fit Patients with Core-Binding Factor Acute Myeloid Leukemia: Preliminary Results

Georgina Gener-Ricos, Gautam Borthakur, Koji Sasaki, Guilin Tang, Guillermo Montalban-Bravo, Elias Jabbour, Maro Ohanian, Musa Yilmaz, Fadi G. Haddad, Kelly S. Chien, Jo Ishizawa, Nicholas J. Short, Abhishek Maiti, Mahesh Swaminathan, Guillermo Garcia-Manero, Naval Daver, Courtney D. DiNardo, Farhad Ravandi, Tapan M. Kadia
Journal: Blood
Blood (2023) 142 (Supplement 1): 2903.
https://doi.org/10.1182/blood-2023-187795
Published: 2023
Journal Articles

A Phase II Study of Low-Intensity Chemotherapy (Mini-Hyper-CVD) and Ponatinib Followed By Blinatumomab and Ponatinib in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Wei-Ying Jen, Elias Jabbour, Fadi G. Haddad, Lewis Nasr, Nicholas J. Short, Marianne Zoghbi, Cedric Nasnas, Ghayas C. Issa, Musa Yilmaz, Naval Daver, Naveen Pemmaraju, Lucia Masarova, Farhad Ravandi, Nitin Jain, Wuliamatu Deen, Christopher Loiselle, Lourdes Waller, Glenda Banks, Rebecca Garris, Hagop M. Kantarjian
Journal: Blood
Blood (2023) 142 (Supplement 1): 2868.
https://doi.org/10.1182/blood-2023-182997
Published: 2023
Journal Articles

Chemotherapy-Free Combination of Blinatumomab and Ponatinib in Adults with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updates from a Phase II Trial

Fadi G. Haddad, Elias Jabbour, Nicholas J. Short, Nitin Jain, Xuelin Huang, Guillermo Montalban-Bravo, Tapan M. Kadia, Naval Daver, Cedric Nasnas, Ejiroghene Mayor, Patrice Eric Nasnas, Wuliamatu Deen, Marianne Zoghbi, Jennifer Thankachan, Christopher Loiselle, Rebecca Garris, Farhad Ravandi, Hagop M. Kantarjian
Journal: Blood
Blood (2023) 142 (Supplement 1): 2827.
https://doi.org/10.1182/blood-2023-188064
Published: 2023
Journal Articles

“Dose-Dense” Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves High Rates of Rapid MRD-Negativity in Patients with Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: A Retrospective Analysis

Trevor Jamison, Hagop M. Kantarjian, Shilpa Paul, Branko Cuglievan, David McCall, Nitin Jain, Fadi G. Haddad, Kayleigh R. Marx, Caitlin R Rausch, J. Michael Savoy, Lewis Nasr, Cedric Nasnas, Marianne Zoghbi, Rebecca Garris, Farhad Ravandi, Marina Y. Konopleva, Elias Jabbour, Nicholas J. Short
Journal: Blood
Blood (2023) 142 (Supplement 1): 1508.
https://doi.org/10.1182/blood-2023-188530
Published: 2023
Journal Articles

Updated Results from a Phase II Study of Hyper-CVAD, with or without Inotuzumab Ozogamicin, and Sequential Blinatumomab in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia

Daniel Nguyen, Hagop M. Kantarjian, Nicholas J. Short, Nitin Jain, Fadi G. Haddad, Musa Yilmaz, Alessandra Ferrajoli, Tapan M. Kadia, Yesid Alvarado Valero, Abhishek Maiti, Cedric Nasnas, Lewis Nasr, Rebecca Garris, Marina Y. Konopleva, Farhad Ravandi, Elias Jabbour
Journal: Blood
Blood (2023) 142 (Supplement 1): 4245.
https://doi.org/10.1182/blood-2023-190902
Published: 2023
Journal Articles

Phase 2 Study of Dasatinib with and without Venetoclax in Patients with Early Chronic Phase Chronic Myeloid Leukemia (ECP-CML)

Fadi G. Haddad, Elias Jabbour, Koji Sasaki, Lewis Nasr, Xuelin Huang, Ghayas C. Issa, Farhad Ravandi, Guillermo Garcia-Manero, Tapan M. Kadia, Naval Daver, Yesid Alvarado Valero, Cedric Nasnas, Maro Ohanian, Nicholas J. Short, Lucia Masarova, Marianne Zoghbi, Patrice Eric Nasnas, Guillermo Montalban-Bravo, Jeffrey Skinner, Sherry Pierce, Michael Andreeff, Hagop M. Kantarjian
Journal: Blood
Blood (2023) 142 (Supplement 1): 870.
https://doi.org/10.1182/blood-2023-188236
Published: 2023